Senti Biosciences clears $2M third-tranche note sale to NSG
Senti Biosciences amended its Securities Purchase Agreement on September 1, 2026 to permit senior secured convertible notes in more than two tranches, authorizing a $2.0 million third-tranche issuance to NSG BioInnovation Fund with CPIF II-7 consent.